GW Pharmaceuticals Shares Jump Following Price Target Raise
In a note released Monday morning, Piper Jaffray made a big raise to the price target of GW Pharmaceuticals (NASDAQ: GWPH) from $97 to $147, citing the potential of GW's Epidiolex to treat epilepsy.
The analysts at Piper Jaffray say that the unique safety/CNS profile make the drug an attractive way to treat epilepsy.
Additionally, the analysts noted that they do not believe INSYS Therapeutics will be able to compete on price.
Following the note, shares of GW Pharmaceuticals are up over six percent in the pre-market.
Latest Ratings for GWPH
|Sep 2016||Morgan Stanley||Maintains||Overweight|
|Sep 2016||Cantor Fitzgerald||Maintains||Buy|
|Jun 2016||Janney Capital||Initiates Coverage on||Sell|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.